or Try an Advanced Search...

    Monogenic Stocks List

    Symbol Grade Name % Change
    PASG D Passage Bio, Inc. 4.69
    RYTM D Rhythm Pharmaceuticals, Inc. -1.09
    SGMO F Sangamo BioSciences, Inc. 4.93
    TSHA D Taysha Gene Therapies, Inc. 0.96
    VYGR D Voyager Therapeutics, Inc. 0.70
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biotechnology Gene Therapy Huntington's Disease Life Sciences Lipid Storage Disorders Medicine Monogenic Diseases Organ Systems Rare Diseases Amyotrophic Lateral Sclerosis Ataxia Biopharmaceutical Blastoma Cell Product Central Nervous System Disorders Deficiency Deficiency Syndrome Dow Agrosciences Emerging Technologies Friedreich's Ataxia

    Related ETFs - A few ETFs which own one or more of the above listed Monogenic stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 1.76
    SBIO C ALPS Medical Breakthroughs ETF 1.48
    HELX C Franklin Genomic Advancements ETF 1.23
    XBI C SPDR S&P Biotech ETF 1.12
    IBRN D iShares Neuroscience and Healthcare ETF 0.74
    View all Monogenic ETFs...
    Compare ETFs
    Compare HELX to XBI Compare SBIO to HELX Compare SBIO to XBI

        Monogenic Stocks Recent News

        Date Stock Title
        May 16 VYGR Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
        May 15 TSHA Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript
        May 15 TSHA Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
        May 14 TSHA Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
        May 14 TSHA Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.01, revenue of $3.41M beats by $0.85M
        May 14 TSHA Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
        May 14 TSHA Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset
        May 14 VYGR Q1 2024 Voyager Therapeutics Inc Earnings Call
        May 14 VYGR Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript
        May 14 VYGR Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
        May 13 VYGR Voyager Therapeutics up 8% following quarterly beats
        May 13 TSHA Taysha Gene Therapies Q1 2024 Earnings Preview
        May 13 VYGR Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
        May 13 VYGR Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M
        May 13 VYGR Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
        May 12 SGMO US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
        May 12 SGMO Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
        May 11 SGMO Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)
        May 10 SGMO Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
        Related Industries: Biotechnology
        Related Stock Lists: Biotechnology Gene Therapy Huntington's Disease Life Sciences Lipid Storage Disorders Medicine Monogenic Diseases Organ Systems Rare Diseases Amyotrophic Lateral Sclerosis Ataxia Biopharmaceutical Blastoma Cell Product Central Nervous System Disorders Deficiency Deficiency Syndrome Dow Agrosciences Emerging Technologies Friedreich's Ataxia
        Monogenic

        Browse All Tags